As per reports, Merck & Co., Inc.(MRK) Inc. has entered into a definitive agreement with Alydia Health, following the spinoff of its women’s health under the new company, Organon. Organon, a global healthcare company will acquire Alydia Health, focusing on improving the overall health of women.
Founded in 2010, Alydia Health is a medical device company working on preventing maternal mortality and morbidity due to one of the most common complications of birth, postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. Alydia’s device, the Jada System, is designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth. PPH may result in pharmacologic treatment in up to 10% of mothers resulting in an emergency intervention leading to hysterectomy, blood transfusions, and, in some cases, even maternal death.
“The acquisition aligns with Organon’s strategy to become a global leader in women’s health by focusing our product development on her unmet medical needs. We believe that Organon’s strong global commercial footprint in reproductive health, in conjunction with Alydia’s rapidly growing commercial capabilities in the U.S., will help enable the growth of the Jada® System, including potential expansion into Europe and other developed countries, as well as in the world’s least developed markets where Organon has significant experience creating affordable access.” stated Kevin Ali, chief executive officer, Organon.
The transaction is subject to customary closing conditions and completion of the spinoff of Organon from Merck. Guggenheim Securities represented Alydia Health as its financial advisor. Organon to acquire Alydia Health for up to $240 million total consideration, including $215 million upfront and a $25 million contingent milestone payment.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.